ClinicalTrials.gg
RecruitingNCT07696962Updated Nov 10, 2026

Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease

A Phase 1 interventional study of ChoironeX GalKO Porcine Thymokidney in End Stage Renal Disease, sponsored by Xeno Holdings (US), LLC dba ChoironeX. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Xeno Holdings (US), LLC dba ChoironeX · Phase 1, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now RecruitingStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Planned enrollment
603rd of 638
4 · median 48
Started
2026
with 21 others
Phase 1
89 of 765
8 open now
Primary completion
2028-06
later than 69 of 95 live
Registered
757th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 603rd largest by planned enrollment of the 638 interventional ones that give a count, is one of 22 that started in 2026, is one of 89 in phase 1, reaches primary completion later than 69 of the 95 other live ones, and was the 757th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

59 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a GalKO Porcine Thymokidney can maintain renal function, without the need for dialysis, after transplantation into adult subjects with End Stage Renal Disease.

03

Conditions studied

  • End Stage Renal Disease

Keywords

  • Kidney, Porcine, Xeno-Transplant
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ESRD receiving hemodialysis or peritoneal dialysis for ≥6 months
  • Eligible for kidney transplantation per site criteria
  • \<50% likelihood of receiving a standard deceased-donor kidney transplant within 12 months
  • Blood type and immunologic compatibility with study transplant confirmed by testing
  • EBV seropositive
  • Up to date on recommended vaccinations for individuals
  • Willing to use protocol-required
  • Able to provide and comply with lifelong follow-up

Exclusion criteria

Exclusion Criteria:

  • Requirement for multi-organ transplantation
  • Living donor available who is ABO-incompatible
  • Kidney disease with high risk of post-transplant recurrence
  • Polycystic kidney disease without prior native nephrectomy
  • Unable or unwilling to comply with study procedures
  • History of non-adherence to medical treatment
  • Identified as vulnerable by psychological assessment
  • Significant uncontrolled psychiatric illness
  • Inadequate social support or caregiver unavailable/unwilling
  • Current drug or alcohol misuse
  • Serious non-renal illness with \<1 year
  • \<16 or >35 kg/m²
  • Known hypercoagulable disorder
  • Uncontrolled hypertension or hemodynamic instability at enrollment
  • cardiovascular disease, including poorly controlled coronary artery disease, reduced left ventricular function, recent myocardial infarction or cardiac intervention, or clinically significant arrhythmia requiring treatment
  • Serious liver disease or impaired liver function
  • Diabetes mellitus with poor glycemic control ( >10%)
  • Active infection at time of transplantation
  • Positive serology for , , or
  • Current, active, or untreated tuberculosis
  • within 5 years prior to enrollment, excluding adequately treated non-melanoma skin cancer
  • Current systemic therapy (excluding permitted )
  • Participation in another interventional drug trial within 60 days prior to enrollment
  • Pregnant or breastfeeding
  • Known severe to a required study medication with no acceptable alternative
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    Porcine Thymokidney

    Porcine Thymokidney transplanted into patients with End Stage Renal Disease

    Biological: ChoironeX GalKO Porcine Thymokidney

Interventions

  • BiologicalChoironeX GalKO Porcine Thymokidney

    A constructed thymokidney from a genetically modified porcine donor will be preserved, packaged, transported and transplanted into the study subject at the study site in the same fashion as a human donor kidney. The thymokidney will remain in the subject throughout the subject's lifetime, or until thymokidney explant.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) from Day 0 through Month 6.

    Time frame: 6 months

  2. Overall survival of the recipient without the need for chronic dialysis at Month 6.

    Time frame: 6 months

Secondary outcomes

  1. Overall survival without the need for dialysis at Month 3.

    Time frame: 3 months

  2. Graft survival free from hyperacute rejection at Day 3.

    Time frame: 3 Days

  3. Incidence of acute and chronic xenograft rejection at Day 14, Months 3 and 6.

    Time frame: 6 months

  4. Banff classification of xenograft pathology at biopsy.

    Time frame: 6 months

  5. Renal filtration function as assessed by creatinine clearance (CrCl) by nuclear medicine scan at Day 14, Months 1, 3, and 6.

    Time frame: 6 months

  6. Total number of clinically significant fluid electrolyte, hemodynamic, acid-base, and hematologic abnormalities requiring medical intervention per patient through Month 6.

    Time frame: 6 months

  7. Total number of clinically significant mineral metabolism abnormalities requiring medical intervention per patient through Month 6

    Time frame: 6 months

  8. Incidences of severe proteinuria (i.e., urinary protein: creatinine ratio of >3.5 g/g) per patient through Month 6.

    Time frame: 6 months

  9. Change from baseline in blood pressure at Months 3 and 6.

    Time frame: 6 months

  10. Incidence of porcine-derived infectious complications through Month 6, in study subjects, site staff, or close personal contacts.

    Time frame: 6 months

  11. Incidence of opportunistic infections (excluding zoonoses) through Month 6, in study subjects.

    Time frame: 6 months

  12. Change from baseline in thymokidney size using ultrasound imaging at Day 14, 21, and Months 1-6.

    Time frame: 6 months

  13. New-onset diabetes after transplant (NODAT) through Month 6.

    Time frame: 6 months

  14. Change from baseline in BMI at Months 3 and 6.

    Time frame: 6 months

  15. Change from baseline in subject-reported quality of life at Months 1, 3, and 6 based on the EuroQol 5-Dimension 5-Level Questionnaire.

    Time frame: 6 months

  16. Change from baseline in subject-reported quality of life at Months 1, 3, and 6 based on the Standardized Outcomes in Nephrology Life Subject Questionnaire.

    Time frame: 6 months

  17. Change from baseline in subject-reported quality of life at Months 1, 3, and 6 based on the Kidney Transplant Questionnaire.

    Time frame: 6 months

  18. Change from baseline in subject-reported quality of life at Months 1, 3, and 6 based on the Patient Global Impression of Change Questionnaire.

    Time frame: 6 months

  19. Evaluate allosensitization in recipients of the thymokidney, defined as a >20% increase from baseline in panel reactive antibody (PRA).

    Time frame: 6 months

  20. Duration of initial hospitalization.

    Time frame: 6 months

  21. Duration of ICU care during initial hospitalization.

    Time frame: 6 months

  22. Number of hospitalizations through Month 6.

    Time frame: 6 months

  23. Time to thymokidney explant, and time to restarting dialysis after explant (if relevant).

    Time frame: 6 months

  24. Incidence of temporary dialysis treatments through Month 6.

    Time frame: 6 months

  25. Number of dialysis-free days through Month 6.

    Time frame: 6 months

  26. Time from transplant to first dialysis treatment (if relevant).

    Time frame: 6 months

07

Study locations

1 of 2 sites recruiting
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
    • Xenotransplant Team · Contact929-831-0135
  • Study Site 2
    New York, New York 10016, United States
    Not yet recruiting
    • Research Coordinator · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 19 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 10, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2028 → Jun 2028, on Nov 2, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2028 → Oct 2028, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jul 10, 2026
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
Jun 30, 2028was May 2028
CompletionEst.
Oct 30, 2028was Sep 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
1 site added, 1 site removed. Study Site 2 is now Not yet recruiting
Show site
  • NYU Langone Health · New York, United States
Show 1 removed
  • Study Site 1 · New York, United States
Nov 2, 2026
Start date
Sep 2026→Nov 2026
moved 2 times, Nov 2, 2026 – Nov 10, 2026
Primary completion
May 30, 2028→Jun 30, 2028
Nov 2, 2026
Study completion
Sep 30, 2028→Oct 30, 2028
Nov 2, 2026
Contact
Study contact's phone or email changed: none listed→•••9413. See the current contact
Nov 2, 2026
Show all 2 updates
  1. Nov 10, 2026
    Start date Oct 2026→Nov 2026
    + 1 other change: verification date
  2. Nov 2, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed. Study Site 2 is now Not yet recruiting
    Show site
    • NYU Langone Health · New York, United States
    Show 1 removed
    • Study Site 1 · New York, United States
    Start date Sep 2026→Oct 2026
    Primary completion May 30, 2028→Jun 30, 2028
    Study completion Sep 30, 2028→Oct 30, 2028
    Contact Study contact's phone or email changed: none listed→•••9413. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07696962
Lead sponsor
Xeno Holdings (US), LLC dba ChoironeX
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Gemma Hodgson
Contact
ghodgson@xeno-holdings.com
443-842-0861
Anna Danilewicz
Contact
adanilewicz@xeno-holdings.com
662-300-9413
Anh Nyugen, MD
study director · ChoironeX / Our Hybrid Concepts LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion